A Phase 1 Trial to Evaluate the Safety of IL13Rα2-Targeting Chimeric Antigen Receptor (CAR) T Cells With CRISPR Knockout of TGFβR2 in Patients With Recurrent or Progressive High-Grade Glioma (HGG)
The ongoing Phase 1 trial at City of Hope Medical Center aims to evaluate the safety and tolerability of TGFβR2KO/IL13Rα2 CAR T-cell therapy in patients with recurrent or progressive high-grade glioma, specifically glioblastoma and IDH-mutant astrocytoma. The trial's focus on a genetically modified autologous CAR T-cell approach positions it within the rapidly evolving CAR T-cell therapy market, which has seen significant investment and interest due to its potential to address unmet medical needs in oncology. Given the high incidence of glioblastoma and the limited treatment options available, successful outcomes could lead to substantial market opportunities. The collaboration with the National Cancer Institute (NCI) enhances credibility and may facilitate regulatory pathways. However, the competitive landscape includes established CAR T therapies and emerging candidates targeting similar pathways, necessitating a robust differentiation strategy.
Indication: Recurrent Astrocytoma, IDH-Mutant, Grade 3
Modality: cell therapy
Target: IL13Rα2 and TGFβR2 (CRISPR knockout)
Sponsor: City of Hope Medical Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: IL13Rα2 and TGFβR2 (CRISPR knockout)
View original source fields
Condition raw: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Condition normalized: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: IL13Rα2 and TGFβR2 (CRISPR knockout)
Target normalized: IL13Rα2 and TGFβR2 (CRISPR knockout)